Tang Yuting, Wang Ting, Hu Yaowen, Ji Hongli, Yan Botao, Hu Xiarong, Zeng Yunli, Hao Yifan, Xue Weisong, Chen Zexin, Lan Jianqiang, Wang Yanan, Deng Haijun, Deng Chuxia, Wu Xiufeng, Yan Jun
Department of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Cancer, Nanfang Hospital, The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Department of Oncology, Nanfang Hospital, The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
iScience. 2023 Jun 13;26(7):107116. doi: 10.1016/j.isci.2023.107116. eCollection 2023 Jul 21.
Patient-derived tumor organoids (PDTOs) have the potential to be used to predict the patient response to chemotherapy. However, the cutoff value of the half-maximal inhibition concentration (IC) for PDTO drug sensitivity has not been validated with clinical cohort data. We established PDTOs and performed a drug test in 277 samples from 242 CRC patients who received FOLFOX or XELOX chemotherapy. After follow-up and comparison of the PDTO drug test and final clinical outcome results, the optimal IC cutoff value for PDTO drug sensitivity was 43.26 μmol/L. This PDTO drug test-defined cutoff value could predict patient response with 75.36% sensitivity, 74.68% specificity, and 75% accuracy. Moreover, this value distinguished groups of patients with significant differences in survival benefit. Our study is the first to define the IC cutoff value for the PDTO drug test to effectively distinguish CRC patients with chemosensitivity or nonsensitivity and predict survival benefits.
患者来源的肿瘤类器官（PDTOs）有潜力用于预测患者对化疗的反应。然而，PDTO药物敏感性的半数最大抑制浓度（IC）的临界值尚未通过临床队列数据进行验证。我们建立了PDTOs，并对242例接受FOLFOX或XELOX化疗的CRC患者的277个样本进行了药物测试。在对PDTO药物测试和最终临床结果进行随访和比较后，PDTO药物敏感性的最佳IC临界值为43.26μmol/L。这个由PDTO药物测试定义的临界值可以以75.36%的敏感性、74.68%的特异性和75%的准确性预测患者反应。此外，该值区分了生存获益有显著差异的患者组。我们的研究首次定义了PDTO药物测试的IC临界值，以有效区分具有化疗敏感性或不敏感性的CRC患者并预测生存获益。
